Bulletin: Valeant Pharmaceuticals International Inc. Ratings, Outlook Not Affected By Recent Acquisition Announcements - S&P Global Ratings’ Credit Research

Bulletin: Valeant Pharmaceuticals International Inc. Ratings, Outlook Not Affected By Recent Acquisition Announcements

Bulletin: Valeant Pharmaceuticals International Inc. Ratings, Outlook Not Affected By Recent Acquisition Announcements - S&P Global Ratings’ Credit Research
Bulletin: Valeant Pharmaceuticals International Inc. Ratings, Outlook Not Affected By Recent Acquisition Announcements
Published Aug 05, 2011
811 words — Published Aug 05, 2011
Price Free  |  Buy this Report Now

About This Report

  
Abstract:

BOSTON (Standard&Poor's) Aug. 5, 2011--Standard&Poor's Ratings Services said today that its BB-/Stable/-- corporate credit rating on Mississauga, Ontario-based Valeant Pharmaceuticals International Inc. is unchanged following recent announcements that it will acquire Sanitas Group, Dermik, and Ortho Dermatologics in three separate transactions. This follows our expectation that, on a pro forma basis, any debt incurred to fund these acquisitions, which aggregate approximately $1.3 billion, will keep leverage below the company's stated target of 4x.

  
Brief Excerpt:

RESEARCH Bulletin: Valeant Pharmaceuticals International Inc. Ratings, Outlook Not Affected By Recent Acquisition Announcements Publication date: 05-Aug-2011 Primary Credit Analyst: Michael G Berrian, Boston (1) 617-530-8307; michael_berrian@standardand...

  
Report Type:

Bulletin

Ticker
VRX
Issuer
Bausch Health Companies Inc.
GICS
Pharmaceuticals (35202010)
Sector
Global Issuers
Country
Canada
Region
Canada
Format:
HTML HTML
Buy Now

More from S&P Global Ratings’ Credit Research

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Bulletin: Valeant Pharmaceuticals International Inc. Ratings, Outlook Not Affected By Recent Acquisition Announcements" Aug 05, 2011. Alacra Store. May 24, 2025. <http://www.alacrastore.com/s-and-p-credit-research/Bulletin-Valeant-Pharmaceuticals-International-Inc-Ratings-Outlook-Not-Affected-By-Recent-Acquisition-Announcements-883385>
  
APA:
S&P Global Ratings’ Credit Research. (). Bulletin: Valeant Pharmaceuticals International Inc. Ratings, Outlook Not Affected By Recent Acquisition Announcements Aug 05, 2011. New York, NY: Alacra Store. Retrieved May 24, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/Bulletin-Valeant-Pharmaceuticals-International-Inc-Ratings-Outlook-Not-Affected-By-Recent-Acquisition-Announcements-883385>
  
Free
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.